More articles from Commentary
- ‘Thanks for sharing’: A fictional reflection on shared medical appointments
“I’m not an exhibitionist, Doctor. I came here to see you, not to be part of a medical encounter group.”
- The sad story of Vioxx, and what we should learn from it
The withdrawal of rofecoxib (Vioxx) has important implications both for patients with arthritis and for the pharmaceutical field in general.
- A world without Vioxx: To COX-2 or not to COX-2?
Are all selective COX-2 inhibitors associated with an increased risk for thromboembolic cardiovascular events? And what should we tell patients?
- It’s what’s inside the white coat that counts
Welcoming the first class of the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
- Genetic discrimination arising from cancer risk assessments: A societal dilemma
The right to privacy of one’s most intimate biological secrets must be affirmed.
- The needs of science vs the needs of patients: Ethical concernsin cancer clinical trials
Patients in cancer trials are not data points; they are vulnerable people who often view a clinical trial as their last hope.
- Privacy protection for your patients: Understanding the federal requirements
On April 14, 2003, almost every medical provider in this country must implement new federal privacy rules. Here’s how.
- GUSTO V: Should it affect clinical practice?
The results of GUSTO V were equivocal and should not lead physicians to change how they treat myocardial infarction.
- The dangers of self-monitored dieting: What are our patients really doing?
Patient-monitored diets often leave questions of adherence and safety unanswered.